

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
NONA BIOSCIENCES DEVELOPS THE WORLD’S FIRST
LANGUAGE MODEL TRAINED ON FULLY HUMAN
HEAVY-CHAIN-ONLY ANTIBODIES

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the Company’s shareholders and potential investors about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Nona Biosciences (“**Nona**”), a wholly-owned subsidiary of the Company, has developed HCAbLM, the world’s first language model specifically trained on fully human heavy-chain-only antibodies (HCAbs). The study entitled “A foundation model learns the sequence and functional grammar of fully human heavy-chain-only antibodies” has been published on bioRxiv.

Built on a large-scale repertoire of 31.8 million fully human HCAb sequences from 73 independently immunized HCAb mice, HCAbLM is designed to capture the unique sequence characteristics of fully human HCAbs. The study demonstrates that HCAbLM learns a distinct sequence “grammar” associated with the heavy-chain-only antibody format, reflecting sequence patterns and relationships that are not fully captured by conventional antibody language models. Importantly, the model’s learned representations also demonstrated the ability to transfer to experimentally measured antibody properties, including SEC purity, HIC behavior and thermal stability, highlighting the potential of HCAbLM to support the evaluation and optimization of fully human HCAbs beyond sequence analysis. The development of HCAbLM marks an important advancement in Nona’s application of artificial intelligence (AI) to antibody discovery and development. By combining large-scale antibody repertoires with AI-driven modeling, Nona is building a foundation for more efficient and data-driven antibody design and developability assessment.

ABOUT NONA BIOSCIENCES

Nona Biosciences, a wholly owned subsidiary of HBM Holdings Limited (HKEX: 02142), is a global biotechnology company committed to advancing biotherapeutic innovation through cutting-edge technology platforms and integrated solutions. Nona supports programs with its I to I[®] framework, from early-stage ideas through preclinical research and advancement toward IND and early clinic, spanning target validation and antibody discovery to early development.

Nona's proprietary Harbour Mice® technology platform generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. The HCAb Harbour Mice® is the world's first fully human HCAb transgenic mouse with clinical validation. This unique platform offers exceptional versatility for diverse applications using fully human VHH single-domain antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.

By integrating Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based screening platform), Hu-mAtrIx™ (an AI-driven drug discovery platform), Modalities-on-Demand® (a next-generation modalities solution), and end-to-end preclinical drug development services, Nona Biosciences is dedicated to driving the global invention of transformative next-generation drugs.

Cautionary Statement: We cannot guarantee that any drug candidate will be successfully developed or ultimately marketed by the Company and/or its collaboration partners. Shareholders and potential investors of the Company are advised to exercise due care when dealing with the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 16 September 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang, Mr. Youchen Chen and Dr. Ian Yi Liu as executive Directors; and Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.